Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gemini Space Station Inc (GEMI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Gemini Space Station IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Gemini Space Station Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gemini Space Station Inc trades at $4.02 (market cap $517.11M), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.4× Gemini Space Station Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.

GEMIRXRX
Market Cap
$517.11M$1.78B
Sector
TechnologyHealth
52-Week High
$32.52$6.79
52-Week Low
$3.90$2.84
Enterprise Value
$507.09M$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gemini Space Station Inc

GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.

The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gemini Space Station Inc

Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.

Read more on GEMI

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX